Novel composition and methods of treating a neurodegenerative disease
WO2025052177A3 Publication Date: 2025-04-17THE CHINESE UNIVERSITY OF HONG KONG
5 Cites 0 Cited by
Patent Information
- Application Number
- PCT/IB2024/000496
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-06
- Filing Date
- 2024-09-06
- Publication Date
- 2025-04-17
AI Technical Summary
Technical Problem
Current treatments for Alzheimer's disease (AD) are ineffective in addressing the underlying pathological mechanisms, particularly the interaction between PTEN and PSD95, which contributes to synaptic dysfunction and memory loss.
Method used
The use of specific compounds such as amaranth, isochlorogenic acid B, isochlorogenic acid C, pentagalloylglucose, and hematoporphyrin dihydrochloride to inhibit the interaction between PTEN and PSD95, thereby modulating synaptic plasticity and alleviating AD symptoms.
Benefits of technology
These compounds effectively inhibit the PTEN:PDZ interaction, leading to improved cognitive function and reduced neurodegenerative symptoms in AD models, both therapeutically and prophylactically.
✦ Generated by Eureka AI based on patent content.
Abstract
Compositions and methods to inhibit the interaction between two protein molecules, PTEN and PSD-95, in neurons are provided. The inhibition of the interaction between PTEN and PSD-95 is used in methods of treating Alzheimer's disease. The compositions comprise isochlorogenic acid B, isochlorogenic acid C, and amaranth.
Need to check novelty before this filing date? Find Prior Art